FIELD: medicine.
SUBSTANCE: method involves determining polymorph markers of gene candidates. Genetic analysis of sportsman blood is done and predisposition and protection alleles and genotypes of polymorph markers of gene candidates are determined like T174M marker of AGT gene predisposition allele M and protection allele T, A(-153)G marker of AT2R1 gene predisposition genotypes AG, GG and allele G and protection genotype AA and allele A, A1298C marker of MTHFR gene predisposition genotype CC and allele C and protection allele A, C825T marker of GNB3 gene predisposition genotype CC, Ala(-9)Val marker of SOD2 gene predisposition genotype AA and allele A and protection genotype VV and allele V, T(-262)C marker of CAT gene predisposition genotype CC, Cys311Ser marker of PON2 gene predisposition genotype Ser/Ser and protection genotype Cys/Ser, I/D marker of gene ApoB predisposition genotype I/I and allele I and protecting genotypes I/I allele I and protection ID and DD and allele D for cardiac ischemia cases; Ser447Ter marker of LPL gene predisposition allele Ser and protection allele Ter, Pro12Ala marker of PPARG2 gene predisposition allele Ala and protection genotypes Pro/Pro and allele Pro, A1298C marker of MTHFR gene predisposition allele C and protection genotype AA and allele A, T(9282) marker of CAT gene predisposition genotype TC and protection genotype CC, Lys198Asn of END1 gene predisposition genotype Lys/Lys for hypertension disease cases; 4a/4b marker of NOS3 gene predisposition genotype 4b/4a and allele 4a and protection genotype 4b/4b and allele 4b, A(-153)G of AT2R1 gene predisposition genotypes AG and allele G and protection genotype AA and allele A, A1298C marker of MTHFR gene predisposition genotype CC and allele C and protection allele A, G7831A of gene ACE predisposition genotypes AA and GA and allele A and protection genotype GG and allele G for hypertension heart cases. It gives base for making conclusion about predisposition when quantitative predomination of predisposition genotypes and alleles take place. Equal quantities of predisposition and protection genotypes and alleles or quantitative predomination of protection genotypes and alleles being the case, genetic protection against pathologic changes development is concluded to be available.
EFFECT: high reproducibility, reliability and accuracy of complication development prognosis.
11 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF DETERMINING PREDISPOSITION TO LONG PHYSICAL EFFORT | 2011 |
|
RU2468086C1 |
METHOD FOR GENETIC DIAGNOSTICS OF SUSCEPTIBILITY TO CARDIOVASCULAR DISEASES | 2007 |
|
RU2376372C2 |
APPLICATION OF DNA-DIAGNOSTICS FOR PRESENCE OF POLYMORPHISM R353Q IN GENE OF FACTOR VII OF BLOOD COAGULATION FOR ESTIMATION OF PREDISPOSITION TO DEVELOPMENT OF HABITUAL NONCARRYING OF PREGNANCY AND METHOD OF PREDISPOSITION ESTIMATION TO THIS DISEASE BY MEANS OF ANALYSIS OF COMBINATION OF POLYMORPHISMS C677T OF GENE MTHFR AND OF GENE R353Q OF FACTOR VII | 2006 |
|
RU2330071C1 |
METHOD FOR GENETIC MARKER PREDICTION OF RISK OF GESTOSIS | 2010 |
|
RU2431842C1 |
METHOD OF GENOTYPING HUMAN THIOREDOXINEREDUCTASE-1 rs1128446 GENE POLYMORPHISM | 2011 |
|
RU2458146C1 |
METHOD OF GENOTYPING HUMAN PEROXIREDOXINE-1 rs17522918 GENE POLYMORPHISM | 2011 |
|
RU2458145C1 |
METHOD FOR PREDICTING RISK OF SCHIZOPHRENIA | 2014 |
|
RU2548784C1 |
METHOD FOR DETECTING EARLY PHYSIOLOGICAL CARDIAC MALFUNCTION IN CHILDREN IN CONDITIONS OF CONTAMINATION WITH PHENOL | 2017 |
|
RU2657821C1 |
METHOD FOR EXTENDED SCREENING OF PREDISPOSITION TO CARDIOVASCULAR DISEASES AND BIOCHIP FOR IMPLEMENTING SUCH METHOD | 2010 |
|
RU2453606C2 |
METHOD FOR PREDICTION OF DEVELOPING METABOLIC SYNDROME IN PATIENT SUFFERING ABDOMINAL OBESITY | 2010 |
|
RU2471193C2 |
Authors
Dates
2008-04-20—Published
2006-12-04—Filed